Expert Interview
Discussing the recent results from the Phase 3 CONTACT-02 clinical Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Ticker(s): RHHBY, EXEL, IPSEY- - Emeritus Andrew C. Novick Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic.
- A member of numerous professional societies and scientific advisory boards including the Board of Scientific Counselors of the National Cancer Institute, the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons, the Society of Urologic Oncology, the Society of Pelvic Surgeons, the American College of Surgeons, and the American Urological Association. He served as President of the Society of Urologic Oncology from 2009 - 2011.
- Dr. Klein's clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. Under his direction, the Prostate Cancer Research Program has been recognized as "Program of the Year" by the Cleveland Clinic.
- Currently manages >100 prostate cancer pts
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
